Traders should anticipate downward pressure on RCUS shares due to the failure of a pivotal Phase 3 trial and reduced strategic partnership optionality with Gilead. Monitor upcoming presentations for detailed data from the futility analysis and assess implications for other TIGIT-targeting therapies in development.
Price Chart
Executive Summary
Arcus Biosciences announced the discontinuation of its Phase 3 STAR-121 trial in metastatic non-small cell lung cancer due to futility, based on an independent data monitoring committee's recommendation. Additionally, Gilead will not extend its option rights to Arcus's early-stage pipeline programs beyond July 14, 2026, retaining only limited existing options.
Key Facts
- Phase 3 STAR-121 study evaluating domvanalimab + zimberelimab + chemo vs. pembrolizumab + chemo in first-line metastatic NSCLC discontinued due to futility
- Decision based on pre-planned futility analysis by Independent Data Monitoring Committee (IDMC); safety not assessed at this stage
- Exploratory endpoint showed zimberelimab + chemo performed consistently with pembrolizumab + chemo on overall survival
- Phase 2 EDGE-Lung study also being discontinued
- Gilead will not make option continuation payment, ending its rights to early-stage programs (CCR6, CD89, CD40L) after July 14, 2026
- Gilead retains time-limited options to AB801, AB598, AB102, and an investigational TNF inhibitor
- Arcus regains full rights to casdatifan development program outside of Taiho-licensed territories
Financial Impact
Significant negative impact expected due to loss of late-stage oncology program and reduced partnership value with Gilead; no specific financial figures disclosed
Risk Factors
- Further devaluation of Arcus's immuno-oncology pipeline
- Reduced likelihood of near-term partnership or acquisition interest
- Potential for additional trial discontinuations in related programs
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001724521-26-000021 |
| Document: 0001724521-26-000021-index.html | 0001724521-26-000021 |
| Document: 0001724521-26-000021.txt | 0001724521-26-000021 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Jul 9, 2026 12w ago | 144 | $28.92 $28.62 | ▼ −1.04% | ▼ −3.46% | $24.27 (−16.08%) |
Apr 21, 2026 23w ago | DEFA14A | $26.62 $22.75 | ▼ −14.54% | ▼ −17.70% | $24.27 (−8.83%) |
Apr 20, 2026 23w ago | 8-K | $22.74 $23.40 | ▼ −2.90% | ▲ +1.30% | $24.27 (−6.73%) |
Apr 8, 2026 25w ago | 144 | $23.28 $26.00 | ▲ +11.68% | ▲ +4.12% | $24.27 (+4.25%) |
Feb 25, 2026 31w ago | 8-K | $20.27 $21.46 | ▲ +5.87% | ▲ +11.11% | $24.27 (+19.73%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access